Asset Details
Do you wish to reserve the book?
Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
Do you wish to request the book?
Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Dendritic Cell Vaccination of Glioblastoma: Road to Success or Dead End
2021
Overview
Glioblastomas (GBM) are the most frequent and aggressive malignant primary brain tumor and remains a therapeutic challenge: even after multimodal therapy, median survival of patients is only 15 months. Dendritic cell vaccination (DCV) is an active immunotherapy that aims at inducing an antitumoral immune response. Numerous DCV trials have been performed, vaccinating hundreds of GBM patients and confirming feasibility and safety. Many of these studies reported induction of an antitumoral immune response and indicated improved survival after DCV. However, two controlled randomized trials failed to detect a survival benefit. This raises the question of whether the promising concept of DCV may not hold true or whether we are not yet realizing the full potential of this therapeutic approach. Here, we discuss the results of recent vaccination trials, relevant parameters of the vaccines themselves and of their application, and possible synergies between DCV and other therapeutic approaches targeting the immunosuppressive microenvironment of GBM.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Antigens
/ Brain Neoplasms - immunology
/ Brain Neoplasms - prevention & control
/ Cancer Vaccines - administration & dosage
/ Cancer Vaccines - immunology
/ Dendritic Cells - immunology
/ Edema
/ Erythema
/ Fever
/ Glioblastoma - prevention & control
/ Glioma
/ Humans
/ Outcome Assessment, Health Care
/ Patients
/ Peptides
/ Tumor Microenvironment - drug effects
/ Tumor Microenvironment - immunology
/ Tumors
/ Vaccines
/ Vomiting
